Michael Chorev, Ph.D. is an Associate-in-Medicine at Brigham and Women’s Hospital, an Associate Professor of Medicine (Biochemistry) at the Harvard Medical School and a faculty member of the Laboratory for Translational Research at the Department of Medicine of Brigham and Women’s Hospital. He led the development of the key reagents used in the diagnosis of glycated CD59. He has co-authored over 200 scientific articles and reviews in journals, chapters in monographs and books, and over 40 awarded and filed patents. He serves as an Editor for Journal of Peptide Science and is the recipient of the 2013 Vincent du Vigneaud Award from the American Peptide Society. Prof. Chorev is co-inventor of ladostigil and rivastigmine (Exelon®). Previously, Prof. Chorev held the Drs. Margaret and Henry Zentner Professor of Pharmaceutical Chemistry Chair at Hebrew University.
Prof. Chorev received his B.Sc., M.Sc. and Ph.D. from the Hebrew University and completed his post-doctoral training at University of California, San Diego.
Alissa Dangel, M.D. is an obstetrician and gynecologist at an academic teaching hospital. She has been in practice for 8 years as an OB/GYN and has particular expertise in the management of gestational diabetes. Her clinical work also includes experience in the global health arena through volunteer work in a rural area of Nicaragua. Dr. Dangel received her B.S. in environmental science from the University of Rochester and completed her M.D. at the University of Massachusetts Medical School. She completed her residency in the department of obstetrics and gynecology at the University of Maryland Medical Center. Dr. Dangel is a fellow of the American College of of Obstetricians and Gynecologists (ACOG) and a member of the Massachusetts Medical Society. She is board certified by the American Board of Obstetrics and Gynecology.
Christopher de Souza is a Director at Broadview Ventures in Boston. He started his pharmaceutical career at Novartis as senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances. After Novartis, Christopher was VP of Business Development at SkyePharma US and also founded a business development consulting practice.
Dr. de Souza received an MBA from Rutgers University and a Ph.D. in physiology from Louisiana State University. He completed his post-doctoral training at “The Upjohn Company” and the Joslin Diabetes Center/Harvard Medical School.
Jose Halperin, M.D. is a physician and researcher at Brigham and Women’s Hospital, where he serves as Director of the Laboratory for Translational Research in the Division of Hematology, and an Associate Professor of Medicine at Harvard Medical School. He is a pioneer in the understanding of the role of the complement system and the complement regulator CD59 in the pathogenesis of diabetes complications. Dr. Halperin holds over 40 awarded or filed patents, several of which have been licensed by Harvard University to companies working on bringing his inventions to the marketplace. Previously, Dr. Halperin founded and was a board member of Best Doctors, Inc. Dr. Halperin is also a founder and board member of Bioambar, SPA.
Dr. Halperin earned his M.D. degree from the University of Buenos Aires School of Medicine.
Hunt is an experienced financial, strategic and biomedical executive with over 30 years of broad-based global financial, investment banking, private equity and corporate operating experience in public and private healthcare companies. He is currently the Chief Business Officer of TISSIUM, a Paris-based medical device company which is developing products for atraumatic tissue reconstruction. He also advises a range of global medical device and diagnostics companies on business and financing strategy and is the Managing Partner of Sachuest Partners.
Hunt received his Master of Arts in International Economics from The Johns Hopkins University School of Advanced International Studies (SAIS) and graduated Cum Laude with his Bachelor of Arts from Boston University. He has also achieved an Executive Certificate in Financial Management from the Graduate School of Business of Stanford University.
Executive Vice President, Research and Development
Dr. Kumar serves as the Executive Vice President of Research and Development at Mellitus leading all aspects of product development. He has nearly 30 years of experience in academia, biotech and diagnostics industries. Previously, he served as Vice President of Diagnostic Technologies at BOA Biomedical a portfolio company of Miraki Innovation, where he managed sepsis diagnostics and therapeutic development, clinical studies and regulatory activities. Dr. Kumar has a breadth of experience in developing a wide variety of IVD platforms and diagnostic products for diseases including Covid-19, HIV, Dengue, Malaria, Typhoid, Anthrax, Chagas, Leishmania, Clostridium difficile, UTI infections, blood chemistry (Glucose, cholesterol, glycosylated hemoglobin, ALT, AST, triglycerides, creatinine etc.), bladder and breast cancer. Additionally, he is experienced in bringing IVDs to market through FDA clearance and CE marking. Prior to BOA he was a Senior Director at Chembio Diagnostics, where he was instrumental in managing research and development of point-of-care IVD devices for a number of infectious diseases. Prior to Chembio, he held various roles of increasing responsibility at First Light Diagnostics, Diagnostics For All, Matritech, Mass Diagnostics and Ranbaxy Laboratories.
Dr. Kumar received his Masters and Ph.D. in Biochemistry from Aligarh University and Central Drug Research Institute, India. He worked as a post-doctoral fellow and instructor at University of Illinois at Chicago and Harvard Medical School (Dana-Farber Cancer Institute, Boston).
Thomas J. Musci, MD served from 2012 to 2016 as Chief Medical Officer at Ariosa Diagnostics, which was acquired by Roche Diagnostics. Dr. Musci held past positions in the maternal-fetal medicine program at the California Pacific Medical Center in San Francisco, as Associate Clinical Professor at the University of California School of Medicine, and as Director of Clinical Affairs, Predictive Health at Novartis Diagnostics, Inc. Dr. Musci served as the past chair of the Committee on Genetics for the American Congress of Obstetricians and Gynecologists (ACOG), and as a member of the Professional Practice Guidelines Committee for the American College of Medical Genetics (ACMG). Dr. Musci is on the editorial advisory board of the American Journal of Obstetrics and Gynecology and is an ad hoc peer reviewer of several professional publications. In addition, he has authored and co-authored many publications on topics including cell-free DNA technology, preeclampsia, fibroblast growth factor, FISH, gene expression, and prenatal screening.
Dr. Musci graduated from Georgetown University School of Medicine and continued his medical training at the University of California by completing an internship and a residency in obstetrics and gynecology; fellowships in maternal-fetal medicine, cardiovascular research, and medical genetics; and postdoctoral research with Marc Kirschner, PhD, in the department of biochemistry and biophysics. He is board certified in obstetrics and gynecology, maternal-fetal medicine, and medical genetics.
Mr. Tagliamonte has more than 30 years of biotech industry experience with responsibility for business development, business and commercial operations, strategic planning, finance and legal functions growing established and emerging life sciences companies. He serves on the Advisory Boards of startups Tantu, Mark Therapeutics and PhagePro. Previously he led corporate development and alliance functions at Oxyrane, Anchor, ImmunoGen and Johnson & Johnson (Ortho Clinical Diagnostics) as well as venture investing with Safeguard. He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad. Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.
Kathy Welch comes to Mellitus from Danforth Advisors and has over 20 years’ experience at the Controller and CFO level. Ms. Welch is an accomplished accounting professional with extensive experience assisting companies as they meet the challenges of growth, transition and automation, while continually improving accounting control and financial reporting.
Ms. Welch is a Certified Public Accountant and graduated summa cum laude with a B.S. and B.A. from Bryant University.
Dr. Xing Zhao serves as the Founding Partner of Orient Life Capital Partner, and the President of Orient Life Investment Holding Company in Cambridge, Massachusetts. Prior to founding Orient Life, Dr. Zhao was the Instructor of Orthopedic Surgery at Massachusetts General Hospital and Harvard Medical School and then later served as the R&D Director and Chair of Research Steering Committee for Vericel Corporation. In addition to serving on the Mellitus Board, Dr. Zhao also serves on the Board of SQZ Biotechnologies and SMOC Therapeutics.
Dr. Zhao obtained his M.D. from Xiangya Medical School and Central South University, China, with residency training in Plastic and Reconstructive Surgery from Zhongshan Hospital and Fudan University, Shanghai, China. He received his Ph.D. in Regenerative Medicine from Utrecht University, the Netherlands and completed a post-doctoral research fellowship at Harvard Medical School. Dr. Zhao also received a certificate of executive education in Leadership and Management from Sloan Management School, MIT.